Claims for Patent: 8,735,366

Summary for Patent: 8,735,366

Title:	Pre-MRNA trans-splicing molecule (RTM) molecules and their uses
Abstract:	The present invention relates to specific and markedly improved pre-mRNA trans-splicing molecule (RTM) molecules which are designed to correct specific genes expressed within cells to be targeted, and which are associated with epidermolysis bullosa, cystic fibrosis, pachyonychia congenital, and psoriasis or neurodermitis, as well as cancers of the skin. In particular, the RTMs of the present invention are genetically engineered to interact with a specific target pre-mRNA expressed in cells to be targeted so as to result in correction of genetic defects or reprogramming of gene expression responsible for a variety of different skin disorders.
Inventor(s):	Bauer; Johann (Salzburg, AT), Mitchell; Lloyd G. (Bethesda, MD)
Assignee:
Application Number:	13/056,449
Patent Claims:	1. A pre-mRNA trans-splicing molecule (RTM), comprising a) at least one binding domain that targets binding of the molecule to a pre-mRNA expressed within a cell, wherein said binding domain consists of a sequence complementary to an exonic sequence of a mammalian gene; b) at least one splicing domain containing motifs necessary for a trans-splicing reaction to occur, and c) at least one coding domain, wherein said coding domain encodes at least one exon of a mammalian gene selected from the group consisting of cystic fibrosis transmembrane conductance regulator (CFTR), integrins, TNF-alpha, interleukins, the immunoglobulin superfamily, kallikreins, matrix metalloproteinases, keratins, collagens, and laminins. 2. The RTM according to claim 1, wherein said mammalian gene is selected from the group consisting of the genes plectin, keratin 14, keratin 5, keratin 6, collagen type 7, collagen type 17, laminin A3, laminin B3, g2, integrin .beta.4, a6, CFTR, ICAM-1, and interleukin-10 (IL-10). 3. The RTM according to claim 1, wherein said RTM comprises a coding domain of exons x to y, where x is an integer selected from 1 or 2 to the maximal number of exons, and y is an integer selected from 0 and x+1, with x+1 being limited by the maximal number of exons of said gene. 4. The RTM according to claim 1, wherein said nucleic acid molecule further comprises at least one safety sequence in said splicing domain and/or at least one sequence complementary to a neighboring exon sequence. 5. The RTM according to claim 1, wherein the binding of the molecule to the target pre-mRNA is mediated by complementarity, triple helix formation, or protein-nucleic acid interaction. 6. The RTM according to claim 1, further comprising at least one intron and/or exon, derived from other genes, in order to provide additional desired functionalities, and/or wherein the exon to be trans-spliced comprises naturally occurring or artificially introduced stop-codons in order to reduce gene expression or contains other sequences which produce an RNAi-like effect. 7. The RTM according to claim 1, further comprising a 3'UTR improving trans-splicing efficiency, expression and/or RNA stability. 8. The RTM according to claim 1, which is a DNA, RNA, DNA/RNA hybrid, or nucleic acid analog molecule. 9. A recombinant expression vector, comprising an RTM according to claim 1. 10. The vector according to claim 9, wherein said vector is a eukaryotic expression vector. 11. The vector according to claim 9, wherein said vector furthermore comprises skin-cell specific regulatory elements for regulating transgene expression. 12. A recombinant skin cell comprising an RTM-molecule according to claim 1. 13. A pharmaceutical preparation, comprising a physiologically acceptable carrier and the RTM according to claim 1. 14. A method for treating a disease of the skin or other epithelia, comprising administering to a patient in need a therapeutically effective amount of a medicament comprising an RTM-according to claim 1. 15. The method according to claim 14, wherein said medicament is applied to the skin or systemic circulation. 16. The method according to claim 14, wherein said disease is selected from epidermolysis bullosa, cystic fibrosis, pachyonychia congenita, autoimmune diseases and cancers of the skin. 17. A method for correcting a genetic defect in a subject comprising administering to said subject an RTM according to claim 1. 18. The method according to claim 17, wherein said correcting comprises reprogramming a gene that plays a specific role in a disease selected from epidermolysis bullosa, cystic fibrosis, pachyonychia congenita, autoimmune diseases and cancers of the skin. 19. The recombinant skin cell, according to claim 12, which is a recombinant keratinocyte, fibroblast or endothelial cell.

Details for Patent 8,735,366

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2028-07-30
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2028-07-30
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2028-07-30